Gazyva misses PFS endpoint in first-line DLBCL study

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said Gazyva obinutuzumab plus CHOP chemotherapy missed

Read the full 151 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE